Bupropion HCL ER

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-21-R-0105

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation for the national contract procurement of Bupropion HCL ER, a pharmaceutical product classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505 (Drugs and Biologicals). This ongoing procurement activity, identified by solicitation number SPE2D2-21-R-0105, is designed to ensure a reliable and compliant supply of Bupropion HCL ER to meet the needs of federal stakeholders. The scope of this contract encompasses the manufacturing and delivery of Bupropion HCL ER in accordance with federal requirements, with the intent to maintain a consistent and secure supply chain for this critical medication. The contract is structured as a national contract, indicating broad distribution and supply responsibilities across multiple federal facilities or agencies. Recent modifications to the contract reflect the evolving regulatory and operational landscape. Notably, Modification P00008 invokes option year 3, extending the contract’s period of performance and affirming the government’s ongoing need for these pharmaceutical supplies. Previous modifications have included the invocation of option year 2 (P00006), the incorporation of Federal Acquisition Regulation (FAR) 52.204-30 to address Federal Acquisition Supply Chain Security Act Orders (P00005), and the implementation of Department of Defense (DoD) Class Deviations 2025-O0003 and 2025-O0004 (P00007), which may affect compliance and reporting requirements. The primary objectives of this procurement are to secure a dependable source of Bupropion HCL ER, ensure adherence to federal supply chain security standards, and maintain compliance with all applicable acquisition regulations. Contractors are expected to deliver pharmaceutical products that meet stringent quality and regulatory standards, with all deliverables conforming to the specifications outlined in the solicitation and its subsequent modifications. DLA Troop Support, the contracting entity, operates as a federal office responsible for the acquisition and distribution of medical and pharmaceutical supplies to the Department of Defense and other federal agencies. The primary point of contact for this solicitation is Kyle Lewicki ([email protected], 445-737-0977), with Jason C. Wray ([email protected], 445-737-6304) serving as the secondary contact. This solicitation is currently active, with documentation and attachments available for review via the official SAM.gov opportunity page (https://sam.gov/opp/d2713ea231544d89b653a39e3fbe278e/view). Interested contractors should review all posted modifications and attachments to ensure a comprehensive understanding of the requirements and compliance obligations. While specific set-aside requirements or special considerations are not detailed in the provided information, contractors should be prepared to demonstrate their capability to meet federal pharmaceutical supply standards and respond to any regulatory changes incorporated through contract modifications. In summary, this opportunity represents a significant and ongoing requirement for the supply of Bupropion HCL ER under a national contract framework, with a strong emphasis on regulatory compliance, supply chain security, and consistent product quality. Contractors with experience in pharmaceutical manufacturing and federal contracting are encouraged to evaluate their alignment with the stated requirements and engage with the DLA Troop Support contacts for further information.
Documents15